Puma Biotechnology Inc (PBYI): Price and Financial Metrics


Puma Biotechnology Inc (PBYI): $2.00

0.01 (+0.50%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PBYI to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PBYI POWR Grades


  • Value is the dimension where PBYI ranks best; there it ranks ahead of 98.72% of US stocks.
  • The strongest trend for PBYI is in Stability, which has been heading down over the past 179 days.
  • PBYI's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).

PBYI Stock Summary

  • Puma Biotechnology Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 0.21% of US listed stocks.
  • PBYI's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 98.82% of US stocks.
  • The volatility of Puma Biotechnology Inc's share price is greater than that of 96.03% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Puma Biotechnology Inc are AERI, INSG, NSTG, QTWO, and AMWL.
  • PBYI's SEC filings can be seen here. And to visit Puma Biotechnology Inc's official web site, go to www.pumabiotechnology.com.

PBYI Valuation Summary

  • PBYI's EV/EBIT ratio is -16.1; this is 154.95% lower than that of the median Healthcare stock.
  • Over the past 114 months, PBYI's EV/EBIT ratio has gone up 6.
  • PBYI's price/sales ratio has moved NA NA over the prior 114 months.

Below are key valuation metrics over time for PBYI.

Stock Date P/S P/B P/E EV/EBIT
PBYI 2021-08-31 1.2 10.5 -8.8 -16.1
PBYI 2021-08-30 1.2 10.5 -8.9 -16.2
PBYI 2021-08-27 1.2 10.6 -8.9 -16.3
PBYI 2021-08-26 1.2 10.1 -8.5 -15.6
PBYI 2021-08-25 1.2 10.4 -8.7 -15.9
PBYI 2021-08-24 1.2 10.3 -8.6 -15.8

PBYI Growth Metrics

    Its year over year net cashflow from operations growth rate is now at 3.74%.
  • The year over year net income to common stockholders growth rate now stands at 67.81%.
  • The 4 year net cashflow from operations growth rate now stands at 119.33%.
PBYI's revenue has moved up $247,078,000 over the prior 52 months.

The table below shows PBYI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 253.155 20.65 -29.126
2021-09-30 250.355 20.45 -48.244
2021-06-30 254.864 11.672 -35.035
2021-03-31 272.062 27.974 -26.534
2020-12-31 225.11 0.773 -59.995
2020-09-30 235.475 7.974 -56.2

PBYI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PBYI has a Quality Grade of C, ranking ahead of 66.91% of graded US stocks.
  • PBYI's asset turnover comes in at 1.012 -- ranking 23rd of 682 Pharmaceutical Products stocks.
  • ACAD, TVTX, and CTMX are the stocks whose asset turnover ratios are most correlated with PBYI.

The table below shows PBYI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 1.012 0.749 -0.448
2021-06-30 0.995 0.755 -0.266
2021-03-31 1.058 0.780 -0.137
2020-12-31 0.905 0.825 -0.449
2020-09-30 0.955 0.836 -0.355
2020-06-30 1.008 0.842 -0.212

PBYI Price Target

For more insight on analysts targets of PBYI, see our PBYI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.63 Average Broker Recommendation 2.06 (Hold)

PBYI Stock Price Chart Interactive Chart >

Price chart for PBYI

PBYI Price/Volume Stats

Current price $2.00 52-week high $11.95
Prev. close $1.99 52-week low $1.60
Day low $1.90 Volume 414,100
Day high $2.06 Avg. volume 498,406
50-day MA $2.60 Dividend yield N/A
200-day MA $4.02 Market Cap 89.95M

Puma Biotechnology Inc (PBYI) Company Bio


Puma Biotechnology is a development stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of products for the treatment of various forms of cancer. The company was founded in 2010 and is based in Los Angeles, California.


PBYI Latest News Stream


Event/Time News Detail
Loading, please wait...

PBYI Latest Social Stream


Loading social stream, please wait...

View Full PBYI Social Stream

Latest PBYI News From Around the Web

Below are the latest news stories about Puma Biotechnology Inc that investors may wish to consider to help them evaluate PBYI as an investment opportunity.

Will Puma Biotech (PBYI) Report Negative Q4 Earnings? What You Should Know

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call at 1:30 pm PST on March 3 to review its fourth quarter and full year 2021 financial results.

Business Wire | February 16, 2022

Puma Biotechnology reports inducement awards under Nasdaq listing rule

Puma Biotechnology (PBYI) has announced that the Compensation Committee of Pumas Board approved the grant of inducement restricted stock unit awards covering an aggregate of 24,375

Seeking Alpha | February 3, 2022

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES, February 03, 2022--Puma Biotechnology reported that inducement awards were granted to new hires in January 2022, as required under Nasdaq Listing Rule 5635(c)(4) .

Yahoo | February 3, 2022

Puma Biotech''s Nerlynx Included In NCCN Guidelines For Breast Cancer

The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) has been updated for breast cancer treatment and includes two essential changes for Puma Biotechnology Inc (NASDAQ: PBYI ) Nerlynx (neratinib). The first update added Nerlynx to the body of the guidelines for treating adjuvant HER2-positive Breast Cancer, with Full story available on Benzinga.com

Benzinga | January 13, 2022

Read More 'PBYI' Stories Here

PBYI Price Returns

1-mo -26.47%
3-mo -9.09%
6-mo -37.11%
1-year -81.33%
3-year -87.11%
5-year -96.20%
YTD -34.21%
2021 -70.37%
2020 17.26%
2019 -57.00%
2018 -79.41%
2017 221.99%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8949 seconds.